Tepotinib is a TKI that selectively binds MET to promote tumor cell death and in the phase II VISION trial, tepotinib had an ORR 46% (95% CI 36–57) with median DOR 11.1 months (95% CI 7.2-NR) [59]. This evidence concerns the gene MET and neoplasm.